JD Supra Law

JANUARY 29, 2025

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement agreement between Amgen and Celltrion resolving the BPCIA litigation regarding Celltrions denosumab biosimilar, CT-P41.. By: Goodwin

Settlement 68

Settlement Litigation 68

JD Supra Law

MARCH 11, 2025

On March 7, 2025, the District Court for the District of New Jersey entered a Stipulation and Order of Dismissal Without Prejudice in view of a settlement agreement between Amgen and Fresenius Kabi resolving the BPCIA litigation regarding Freseniuss denosumab biosimilar, FKS518.. By: Goodwin

Settlement 59

Settlement Litigation 59

LexBlog IP

MARCH 6, 2024

announced it has signed a settlement agreement with Bayer Inc. The settlement resolves multiple patent infringement proceedings in the Federal Court of Canada. Under the agreement, Biocon can launch YESAFILI in Canada no later than July 1, 2025. On March 4, Biocon Biologics Ltd. and Regeneron Pharmaceuticals, Inc.

Marketing 52

Marketing Marketing Settlement Litigation 52

The IPKat

MARCH 13, 2025

The judgment carefully considers some of the issues around how trade marks are described and presented on the register, with the court finding that the mark was validly registered: Babek International Ltd v Iceland Foods Ltd [2025] EWHC 547 (IPEC) What is the case about? What was the hearing about?

Registration 45

Registration Intellectual Property Litigation Settlement 45

JD Supra Law

AUGUST 3, 2023

Welcome to our quarterly update relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster biologics. Notably, since our last update, Janssen and Amgen reached a settlement allowing for the launch of Amgen’s biosimilar to Stelara no later than January 1, 2025. By: Morgan Lewis

Settlement 52

Settlement Litigation Patent 52

The IPKat

FEBRUARY 29, 2024

This New York action has been stayed pending resolution of the English litigation. It is likely therefore that it will stand to be determined by a High Court judge some time in 2025. Are you experienced” The most recent hearing in the English proceedings was to consider Sony’s application for summary judgment (i.e.

Reporting 111

Reporting Copyright Contracts Settlement 111

SpicyIP

MARCH 15, 2024

Since parties could not arrive at a settlement, ID initiated patent infringement proceedings against the defendants in UK, Germany and India. If the trial spills over to 2025, the defendants will have to bear the cost for that as well. The parties commenced joint negotiations in 2021.

Patent Infringement 59

Patent Infringement Settlement Patent Licensing 59

Biswajit Sarkar Copyright Blog

DECEMBER 19, 2023

As India aims for a $5 trillion economy, the MSME ministry sets ambitious goals, aiming to elevate their GDP contribution by up to 50% by 2025. This made it intricate and perplexing for litigants, especially small business owners reliant on consistent cash flow.

Settlement 52

Settlement Intellectual Property Registration Design 52

LexBlog IP

NOVEMBER 5, 2023

As we covered previously , Janssen and Amgen settled their BPCIA litigation regarding Amgen’s ustekinumab biosimilar product in May 2023. ” (CMS’s position on this has been challenged in pending litigation.) WEZLANA is the first product to be approved as a biosimilar to STELARA.

Marketing 40

Marketing Marketing Government Litigation 40

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

Yet 2020 saw a slowdown in biosimilar activity with the lowest number of annual biosimilar approvals since 2016 and fewer product launches than 2019—as well as a decrease in district court litigation and post-grant proceedings. BPCIA Litigation. Antitrust Litigation. No earlier than July 31, 2023 per settlement.

Litigation 52

Litigation Settlement Marketing Marketing 52

LexBlog IP

JANUARY 25, 2024

Janssen and Amgen settled their BPCIA litigation regarding Amgen’s ustekinumab biosimilar product in May 2023. ” (CMS’s position on this has been challenged in pending litigation.) WEZLANA is the first product to be approved as a biosimilar to STELARA.

Marketing 40

Marketing Marketing Licensing Litigation 40

Patently-O

MAY 15, 2024

This wave of RFCs includes significant proposals aimed at adjusting patent fees for fiscal year 2025, refining terminal disclaimer practices, and addressing the impact of artificial intelligence on prior art and patentability. 325(d) considerations, parallel and serial petitions, and settlement-related terminations.

Art 45

Art Intellectual Property Design Designs 45

TorrentFreak

DECEMBER 3, 2024

IBCAP Welcomes Conclusion of Long-Running Litigation In an announcement welcoming the end of the long-running litigation which dates back to 2018, the International Broadcaster Coalition Against Piracy (IBCAP) celebrated the win alongside IBCAP member DISH. 20, 2025,” the statement reads.

Copyright Infringement 57

Copyright Infringement Settlement Copyright Litigation 57

SpicyIP

DECEMBER 31, 2024

Wishing everyone a prosperous and a healthy new year ahead and hoping that 2025 brings in spicier IP developments to the Indian IP regime, making it a more fair, balanced and effective one! Happy 2025! A) Top 10 IP Judgements/Orders (Topicality/Impact) 1. Novex Communications Pvt Ltd v. Under Armour v. And see you in the year ahead!

IP 105

IP Invention Patent Copyright 105